We are pleased to welcome Sofia Håkansson Buch as new CEO of ArgusEye.
Sofia brings extensive experience across biologics and cell therapy, with a background in process development, manufacturing, and commercialization. Her leadership will be instrumental as we continue to scale and expand the reach of our real-time bioprocess monitoring platform.
Torben Jørgensen, Chairman of the Board, comments:
We are pleased to welcome Sofia as the new CEO of ArgusEye at this important stage in the company’s development and commercialization. Her strong industry experience and deep understanding of bioprocessing will be invaluable as we continue to scale the company and bring our technology to a broader market.
Simultaneously, co-founder and current CEO Erik Martinsson will transition to CTO, focusing on advancing our technology and product development.
With this leadership transition, ArgusEye is well-positioned to accelerate growth and deliver greater value to our customers and partners.
